Interview with James Lanthier, CEO of Mindset Pharma

Meet Mindset Pharma, a Leader in the Race to Develop Next-Gen Psychedelic Compounds

Meet Mindset Pharma, a Leader in the Race to Develop Next-Gen Psychedelic Compounds

Episode Summary

In today’s episode of the Psychedelic Spotlight Podcast, James Hallifax sits down with James Lanthier, CEO of Mindset Pharma. Mindset Pharma is a psychedelic medicines company that is working on next-generation psychedelic compounds that are inspired by psilocybin and DMT/ 5-MEO-DMT. The company plans on creating medicines to be used for both psychedelic therapy, and microdoses. On January 5th, Mindset announced that they have partnered with the Japanese pharmaceuticals company Otsuka, to help them develop several new psychedelic medicines. In this conversation, the two James’ discuss all of this and more, getting to the bottom of Mindset’s philosophies and business strategy.

You can find Mindset Pharma trading on the Canadian Securities Exchange under the symbol $MSET and on the American OTC market under the symbol $MSSTF.

*To learn more about Mindset Pharma visit their website: MindsetPharma.com